Novartis' Drug Discovery Head Jay Bradner On What NIBR Is Investing In

 
• By Jessica Merrill

NIBR's Bradner talked to Scrip about how AveXis turbo-charged Novartis' gene therapy development, investing in inflammasome research, and partnering nimbly like a venture capitalist.

James Bradner
Novartis' NIBR President James Bradner

More from Leadership

More from Scrip